The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma ...

This approval introduces the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy in Japan, offering patients a new treatment option. HYQVIA combines subcutaneous immunoglobulin ...

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia ...

Innovative Health Sciences has successfully secured the exclusive Medical Device Regulations Quality Management System ...

Analysts have recently evaluated KORU Medical Systems and provided 12-month price targets. The average target is $4.7, ...

The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first ...

We apologize, but this video has failed to load. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one ...